Gavreto (Pralsetinib)
Gavreto (Pralsetinib)
- Name: Gavreto
- Generic Name: Pralsetinib
- Dosage Form & Strength: Capsules: 100mg
- Manufactured By: Genentech, Inc.
Gavreto is a kinase inhibitor used for the treatment of adult patients with metastatic RET fusion- positive non-small cell lung cancer (NSCLC).
Recommended Dosage: The recommended dosage is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking your dose). Continue treatment with Gavreto (Pralsetinib Capsules) until disease progression or until unacceptable toxicity. In case a dose of Pralsetinib is missed, it can be taken as promptly as possible on the same day. Regular daily dose schedule needs to be resumed the next day. Avoid taking an additional dose in case vomiting occurs but continue with the next dose as scheduled.
- Withhold Pralsetinib 100 mg Capsules for Grade 1/2 reactions until the time of resolution and then resume at a reduced dose. Permanently discontinue for the recurrent ILD/pneumonitis.
- Do not initiate therapy with Pralsetinib in patients with uncontrolled hypertension. Optimize BP prior to initiating Pralsetinib therapy. Monitor BP after 7 days, at least monthly thereafter.
- Monitor ALT & AST before initiating Gavreto 100 mg capsules, every 14 days during the first 3 months, then monthly thereafter. Withhold, reduce dose, or permanently discontinue on behalf of severity.
- Permanently discontinue the treatment with capsules of Pralsetinib in patients with severe or life-threatening hemorrhage.
- Withhold the Gavreto capsules for at least 5 days before elective surgery. Avoid administering for at least 14 days following major surgery and until adequate wound healing.
- Gavreto therapy can cause fetal harm. Advise womens of reproductive age of the potential risk to a fetus and to consider effective non-hormonal contraception.
What documents are required to import GAVRETO to India?
GAVRETO (Pralsetinib) can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is GAVRETO available in India?
GAVRETO (Pralsetinib Capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
GAVRETO (Pralsetinib Capsules) can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of GAVRETO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements
What is the Generic Name for the trade name drug Gavreto® ?
Pralsetinib is Generic Name for the trade name drug Gavreto®.
What is the Manufacturer Name of Gavreto®?
Gavreto® is manufactured by Genentech, Inc.
Is Gavreto® approved by the FDA?
Yes, Gavreto® is approved by the FDA. Date of approval: December 1, 2020.
What is Gavreto®?
Gavreto® is a once-daily oral targeted therapy for people living with RET+Ve (RET+) metastatic NSCLC or advanced thyroid cancer.
What is the dosage and form of Gavreto® available?
Gavreto® is available as Capsules: 100 mg for the oral administration.
How does Pralsetinib work?
Pralsetinib falls under the group of medications called antineoplastics (cancer medicines). It works in order to interfere with the growth of malignant cells, which are eventually destroyed.
Is it safe to buy Gavreto® (Pralsetinib Capsules) online?
Yes, In order to buy Pralsetinib Capsules online, always look for an authentic and WHO-GDP & ISO certified pharmaceutical wholesaler/distributor/supplier.
What are the most common side effects due to Gavreto®?
Most common side effects due to Gavreto® include: fatigue, constipation, hypertension and musculoskeletal pain.
What are the storage conditions of Gavreto®?
Store the capsules at temperature 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F). Protect from the moisture.
How much does Gavreto® cost in India?
You can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in to know the cost of Pralsetinib 100 mg Capsules in India.
What are the Highlights of prescribing information for Gavreto®?
Click Here to download full Gavreto prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.